BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · IEX Real-Time Price · USD
4.450
-0.030 (-0.67%)
At close: May 3, 2024, 4:00 PM
4.500
+0.050 (1.12%)
After-hours: May 3, 2024, 7:59 PM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 536 employees on December 31, 2023. The number of employees increased by 5 or 0.94% compared to the previous year.
Employees
536
Change (1Y)
5
Growth (1Y)
0.94%
Revenue / Employee
$618,306
Profits / Employee
-$422,647
Market Cap
918.17M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 536 | 5 | 0.94% |
Dec 31, 2022 | 531 | 173 | 48.32% |
Dec 31, 2021 | 358 | 112 | 45.53% |
Dec 31, 2020 | 246 | 106 | 75.71% |
Dec 31, 2019 | 140 | 40 | 40.00% |
Dec 31, 2018 | 100 | 15 | 17.65% |
Dec 31, 2017 | 85 | 20 | 30.77% |
Dec 31, 2016 | 65 | -5 | -7.14% |
Dec 31, 2015 | 70 | 20 | 40.00% |
Dec 31, 2014 | 50 | 10 | 25.00% |
Dec 31, 2013 | 40 | 0 | - |
Dec 31, 2012 | 40 | -35 | -46.67% |
Dec 31, 2011 | 75 | -1 | -1.32% |
Dec 31, 2010 | 76 | -3 | -3.80% |
Dec 31, 2009 | 79 | -1 | -1.25% |
Dec 31, 2008 | 80 | -26 | -24.53% |
Dec 31, 2007 | 106 | 21 | 24.71% |
Dec 31, 2006 | 85 | 33 | 63.46% |
Dec 31, 2005 | 52 | 2 | 4.00% |
Dec 31, 2004 | 50 | 4 | 8.70% |
Dec 31, 2003 | 46 | 2 | 4.55% |
Dec 31, 2002 | 44 | -33 | -42.86% |
Dec 31, 2001 | 77 | 11 | 16.67% |
Dec 31, 2000 | 66 | 6 | 10.00% |
Dec 31, 1999 | 60 | 4 | 7.14% |
Dec 31, 1998 | 56 | 1 | 1.82% |
Dec 31, 1997 | 55 | 2 | 3.77% |
Dec 31, 1996 | 53 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
BCRX News
- 2 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - BioCryst to Report First Quarter 2024 Financial Results on May 6 - GlobeNewsWire
- 18 days ago - BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency - GlobeNewsWire
- 5 weeks ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones - GlobeNewsWire
- 2 months ago - BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment - GlobeNewsWire
- 2 months ago - BioCryst Launches ORLADEYO® (berotralstat) in Italy - GlobeNewsWire
- 2 months ago - BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 - GlobeNewsWire